Home › Research › Treatments
L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial
Burke WJ, Roccaforte WH, Wengel SP, Bayer BL, Ranno AE, Willcockson NK.. Journal of the American Geriatrics Society, 1993-11-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Objective To examine the cognitive and behavioral effects of L-deprenyl in persons with mild dementia of the Alzheimer type (DAT) over a 15-month period. Design A 15-month randomized, double-blind, placebo-controlled trial using a parallel-group design. Participants 39 subjects with mild DAT (CDR 1) selected using NINCDS-ADRDA criteria. Outcome measures A battery of neuropsychological tests and clinical rating scales. Results The placebo and L-deprenyl subjects were similar at baseline on the clinical and neuropsychological tests. The total score on the Brief Psychiatric Rating Scale (BPRS) was significantly less after 15 months in subjects taking L-deprenyl. The only individual item of the BPRS which differed between groups was disorientation. There was no evidence of a L-deprenyl effect on any other clinical or neuropsychological measure after 2, 8, or 15 months. Conclusion L-deprenyl did appear to have a slight effect on a single measure of psychopathology, the BPRS. It did not have a measurable impact on any other measure of behavior or cognitive function over a 15-month period in this group of subjects with mild DAT and did not appear to slow the progression of the disease.
What this study adds
Evidence grade: High
This is a trial of 39 participants. In this 15-month trial of 39 people with mild dementia of the Alzheimer type, L-deprenyl produced a significantly lower total score on one psychiatric rating scale but no effect on any other clinical or neuropsychological measure. The authors conclude it did not appear to slow the progression of the disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Burke, W. J., Roccaforte, W. H., Wengel, S. P., Bayer, B. L., Ranno, A. E., & Willcockson, N. K. (1993). L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.1993.tb07306.x
Vancouver
Burke WJ, Roccaforte WH, Wengel SP, Bayer BL, Ranno AE, Willcockson NK. L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. Journal of the American Geriatrics Society. 1993. doi:10.1111/j.1532-5415.1993.tb07306.x. PMID: 8227897.
BibTeX
@article{burke1993-8227897,
author = {Burke, W. J. and Roccaforte, W. H. and Wengel, S. P. and Bayer, B. L. and Ranno, A. E. and Willcockson, N. K.},
title = {{L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial}},
journal = {Journal of the American Geriatrics Society},
year = {1993},
doi = {10.1111/j.1532-5415.1993.tb07306.x},
pmid = {8227897},
url = {https://doi.org/10.1111/j.1532-5415.1993.tb07306.x}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results The placebo and L-deprenyl subjects were similar at baseline on the clinical and neuropsychological tests.
- The total score on the Brief Psychiatric Rating Scale (BPRS) was significantly less after 15 months in subjects taking L-deprenyl.
Why it matters
In this 15-month trial of 39 people with mild dementia of the Alzheimer type, L-deprenyl produced a significantly lower total score on one psychiatric rating scale but no effect on any other clinical or neuropsychological measure. The authors conclude it did not appear to slow the progression of the disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants39
- Evidence strengthHigh
How this study scored 55/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 53 of the 96 points we could judge it on, which is 55 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of the American Geriatrics Society) |
| Journal's citation record | 3 / 4 | Journal of the American Geriatrics Society: journal h-index 344 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 1993 — older than 20 years, still counted |
| Sample size | 1 / 4 | 39 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 4 / 7 | Cited 50 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.4 citations a year over 35 year(s) since 1993 |
| Impact for its field and year | 2 / 6 | Cited 2.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Nancy K. Willcockson holds only 9 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | University of Nebraska Medical Center: institution h-index 666 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 8227897) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 53 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 53 of the 96 points we could judge it on is 55 out of 100. |
| Total | 55 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.